Study to Investigate the Safety, Tolerability, and Pharmacokinetics of DSTA4637S in Participants With Staphylococcus Aureus Bacteremia Receiving Standard-of-Care (SOC) Antibiotics
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Genentech, Inc.
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Body mass index greater than or equal (\>/=) 18 to less than or equal to (\</=) 40 kg/m\^2
At randomization, participants must have \>/=1 blood culture or molecular diagnostic that is positive for Staphylococcal aureus (S. aureus) collected in the previous 120 hours
In the investigator's judgment, an expected treatment duration for S. aureus intravenous infection with anti-staphylococcal SOC antibiotics \>/= 4 weeks
You may not be if
The presence of an intravascular catheter that is not planned to be removed within 96 hours of study randomization
S. aureus bacteremia associated with an intracardiac device and/or intravascular prosthetic material (including hemodialysis access graft)
In the investigator's judgement, S. aureus bacteremia involving infection of a prosthetic joint or vertebral hardware
In participants with cirrhosis, a Child-Pugh Score of Class B or C
Known rifampicin-resistant S. aureus
Anticipated receipt of a rifamycin class (excluding rifaxamin) antibiotic from Day 1 to study completion/discontinuation
In the investigator's judgment, the need for emergent valve surgery at the time of randomization or a high likelihood of cardiac surgery within 3 days after randomization
Polymicrobial bacteremia
Participants with significant immune suppression
Participants with evidence of liver disease
History or presence of an abnormal electrocardiogram (ECG)
Exposure to any biological therapy or investigational biological agent within 90 days prior to the screening evaluation or have received any other investigational treatment 30 days prior to the screening evaluation
